Online Education | Pediatric Drug Therapy 2018
This online lecture series is designed as a pediatric pharmacology update at the advanced practice level. Sessions focus on current recommendations and controversies in drug therapy for common pediatric and adolescent health concerns. Teaching methods include lecture, discussion and case analysis.
This activity set was published June 10, 2018. It will expire June 10, 2021.
For pediatric nurse practitioners, family nurse practitioners, physician assistants, clinical nurse specialists, nurses, respiratory therapists, pharmacists and other interested healthcare professionals.
Objectives for Learning Outcomes
At the conclusion of this activity, participants will be better able to:
- Review updates in the treatment of type 1 and type 2 diabetes in pediatrics.
- Discuss safety of commonly used OTC and prescribed nutritional supplements.
- Review common medication reactions in the pediatric population and clues to more concerning presentations.
- Identify the pharmacodynamics of common chemotherapy agents.
- Discuss categories of illicit drugs, street names, routes of administrations and pattern of use.
Type 1 and Type 2 Diabetes Management Updates in Pediatrics
Nutraceuticals and Pediatrics: Updates and Up-and-Coming
Ode to Better Breathing: Pulmonary Pearls for Asthma
Drug Eruptions in Pediatrics: Is It a Drug Eruption? A Viral Exanthem? or Graft vs Host Disease? Yes!
Chemotherapy and the Trouble it Causes: Common Chemotherapy Agents and Symptom Management of the Pediatric Cancer Patient
Street Narcotics: What Medical Professionals Need to Know
- Watch or listen to one or more presentations.
- Complete a short evaluation for each presentation.
- Finish all activities by the activity expiration date. (We'll remind you 60 days out.)
Alfonzo Armstead, PA-C
Physician Assistant, Endocrinology, Seattle Childrens, Seattle, WA
Corrine Hoeppner, MN, ARNP
Nurse Practitioner, Seattle Childrens Oncology, Seattle Children's, Seattle, WA
Sunita Iyer, ND, LM
Clinical Director and Physician, Eastside Natural Medicine, Kenmore, WA
Brandon James, BS
Detective Sergeant, North Precinct Anti-Crime Team, Seattle Police Dept., Seattle, WA
Marijo Ratcliffe, DNP, ARNP, CPNP
Pediatric Pulmonary Nurse Practitioner, Seattle Children's Hospital
Robert Sidbury, MD, MPH
Professor, Dept. of Pediatrics, Seattle, WA
Michele Acker, MN, ARNP
Pediatric Nurse Practitioner, Anesthesia Clinic, Seattle Childrens Hospital, Seattle
Dora Hall, MN, ARNP
Pediatric Nurse Practitioner, Autism Center, Seattle Children's Hospital, Seattle
Michelle Hayes, MN, ARNP, CPNP
Owner; ARNP, Fir Creek Pediatrics, Lakewood; Clinical Preceptor, UW SON
Helene Law, MSN, ARNP
Pediatric Nurse Practitioner, Dept of Gastroenterology, Seattle Childrens Hospital, Seattle
Joan Riesland, MEd, BSN, RN
Interim Executive Director, Nurse Planner and Continuing Education Specialist, Continuing Nursing Education, UW School of Nursing, Seattle
Disclosures for this educational offering: (What is this?)
- Robert Sidbury, MD, MPH
Grant/Research Support: Site Investigator for Regeneron (Dupilumab for AD), Scioderm (Zublisa for EB)
Advisory Committees or Review Panels: Advisory Board x1 for Pfizer regarding Crisaboroic for AD
- All other speakers and planning committee members — None
- 6.00 Contact hours
- 6.00 Pharmacology hours at the advanced practice level